H.C. Wainwright Has Just Reaffirmed $4.0 Target Price Per Share on Idera (NASDAQ:IDRA) stock, While They’ve Also Reiterated Their “Buy” Rating

February 24, 2018 - By Stephen Andrade

 H.C. Wainwright Has Just Reaffirmed $4.0 Target Price Per Share on Idera (NASDAQ:IDRA) stock, While They’ve Also Reiterated Their

Investors sentiment decreased to 1.36 in Q3 2017. Its down 0.10, from 1.46 in 2017Q2. It dived, as 5 investors sold Idera Pharmaceuticals, Inc. shares while 20 reduced holdings. 11 funds opened positions while 23 raised stakes. 46.97 million shares or 1.60% more from 46.23 million shares in 2017Q2 were reported.

Pennsylvania-based Susquehanna Int Gru Limited Liability Partnership has invested 0% in Idera Pharmaceuticals, Inc. (NASDAQ:IDRA). Blackrock reported 6.52M shares or 0% of all its holdings. Alyeska Inv Gp L P, a Illinois-based fund reported 635,853 shares. Fmr Limited reported 3.27 million shares. Guggenheim Cap Ltd holds 42,712 shares or 0% of its portfolio. Moreover, Tower Research Cap Lc (Trc) has 0% invested in Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) for 12,203 shares. Palo Alto Investors Ltd Llc has invested 0.06% in Idera Pharmaceuticals, Inc. (NASDAQ:IDRA). California State Teachers Retirement System invested 0% of its portfolio in Idera Pharmaceuticals, Inc. (NASDAQ:IDRA). Alps Advsr holds 0% or 147,363 shares in its portfolio. Voya Inv Mgmt Ltd reported 53,499 shares. 61,173 were accumulated by Nationwide Fund Advsrs. State Bank Of America Corporation De invested in 11,247 shares or 0% of the stock. Leavell Invest Mngmt reported 0.02% in Idera Pharmaceuticals, Inc. (NASDAQ:IDRA). Morgan Stanley reported 155,772 shares or 0% of all its holdings. Millennium Mgmt Ltd Co reported 1.63 million shares or 0.01% of all its holdings.

Since October 26, 2017, it had 1 buy, and 2 sales for $7.00 million activity. BAKER BROS. ADVISORS LP had bought 8.00M shares worth $12.00M.

Idera (NASDAQ:IDRA) Rating Reaffirmed

In a note revealed this morning, H.C. Wainwright reconfirmed their “Buy” rating on Idera (NASDAQ:IDRA) shares. The PT indicates a possible upside of 113.90 % from firm’s last price.

Investors sentiment decreased to 1.36 in Q3 2017. Its down 0.10, from 1.46 in 2017Q2. It dived, as 5 investors sold Idera Pharmaceuticals, Inc. shares while 20 reduced holdings. 11 funds opened positions while 23 raised stakes. 46.97 million shares or 1.60% more from 46.23 million shares in 2017Q2 were reported.

Pennsylvania-based Susquehanna Int Gru Limited Liability Partnership has invested 0% in Idera Pharmaceuticals, Inc. (NASDAQ:IDRA). Blackrock reported 6.52M shares or 0% of all its holdings. Alyeska Inv Gp L P, a Illinois-based fund reported 635,853 shares. Fmr Limited reported 3.27 million shares. Guggenheim Cap Ltd holds 42,712 shares or 0% of its portfolio. Moreover, Tower Research Cap Lc (Trc) has 0% invested in Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) for 12,203 shares. Palo Alto Investors Ltd Llc has invested 0.06% in Idera Pharmaceuticals, Inc. (NASDAQ:IDRA). California State Teachers Retirement System invested 0% of its portfolio in Idera Pharmaceuticals, Inc. (NASDAQ:IDRA). Alps Advsr holds 0% or 147,363 shares in its portfolio. Voya Inv Mgmt Ltd reported 53,499 shares. 61,173 were accumulated by Nationwide Fund Advsrs. State Bank Of America Corporation De invested in 11,247 shares or 0% of the stock. Leavell Invest Mngmt reported 0.02% in Idera Pharmaceuticals, Inc. (NASDAQ:IDRA). Morgan Stanley reported 155,772 shares or 0% of all its holdings. Millennium Mgmt Ltd Co reported 1.63 million shares or 0.01% of all its holdings.

Since October 26, 2017, it had 1 buy, and 2 sales for $7.00 million activity. BAKER BROS. ADVISORS LP had bought 8.00M shares worth $12.00M.

Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) Ratings Coverage

Among 4 analysts covering Idera Pharma (NASDAQ:IDRA), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Idera Pharma has $8 highest and $4.0 lowest target. $5.50’s average target is 194.12% above currents $1.87 stock price. Idera Pharma had 7 analyst reports since January 6, 2016 according to SRatingsIntel. Wedbush initiated it with “Outperform” rating and $6.0 target in Wednesday, January 6 report. H.C. Wainwright maintained Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) rating on Thursday, November 16. H.C. Wainwright has “Buy” rating and $4.0 target. The stock of Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) has “Buy” rating given on Thursday, November 9 by Piper Jaffray. The company was maintained on Wednesday, February 1 by Wedbush. The firm earned “Buy” rating on Monday, September 11 by Piper Jaffray.

The stock increased 1.63% or $0.03 during the last trading session, reaching $1.87. About 1.24 million shares traded. Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) has risen 21.13% since February 24, 2017 and is uptrending. It has outperformed by 4.43% the S&P500.

Analysts await Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) to report earnings on March, 21. They expect $-0.08 EPS, down 900.00 % or $0.09 from last year’s $0.01 per share. After $-0.10 actual EPS reported by Idera Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -20.00 % EPS growth.

Idera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of oligonucleotide therapeutics for oncology and rare diseases in the United States. The company has market cap of $365.84 million. It uses two drug discovery technology platforms to design and develop drug candidates, including toll-like receptor targeting technology and third-generation antisense technology. It currently has negative earnings. The company's drug candidates include IMO-2125, an agonist that is in Phase I/II clinical trials in combination with ipilimumab and pembrolizumab for the treatment of anti-PD-1 refractory metastatic melanoma and refractory solid tumors; IMO-8400, an antagonist, which is in Phase II clinical trial for the treatment of dermatomyositis.

More news for Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) were recently published by: Globenewswire.com, which released: “BioCryst Pharmaceuticals and Idera Pharmaceuticals to Present at Two Upcoming …” on February 19, 2018. Prnewswire.com‘s article titled: “Great Point Partners, LLC Opposes The BioCryst Pharmaceutical Proposed Merger …” and published on February 16, 2018 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: